← Back to Patent Explorer
US4378352A Expired / Lapsed US ⏱️ 0.0 years remaining

(2'-5')Oligo-isoadenylate pharmaceutical compositions and method of use

Assignee: Yeda Research and Development Co Ltd
•
Filing: 1980-10-08
•
Granted: 1983-03-29
•
Expires: 2000-10-08
📄 Original PDF 🌐 Google Patents 🔄 Sync Now

Abstract

Abstract The invention relates to a novel process for the production of (2'-5')A(pA) n pA chains wherein n is an integer of from 1 to 6, which comprises polymerizing adenosine (2'-3') monophosphate to obtain a mixture of 2'-5'- and 3'-5'-polyadenylic acid, treating the mixture with ribonuclease P 1 to cleave selectively the 3'-5'-bonds so as to retain the 2'-5'-polymeric moieties with a terminal 5'-phosphate moiety and removing the terminal phosphate groups by means of alkaline phosphatase. The mixture may be purified by separation on an anionic ion exchanger and collecting the individual fractions. The invention further relates to pharmaceutical compositions for inhibiting the immune response of mammals which comprise as active ingredient a (2'-5')oligo-isoadenylate defined above. The preferred compositions are those with a preponderance of the trimer.

Inventors

  • 👤 Adi Kimchi
  • 👤 Michel Revel
  • 👤 Sara Rappoport
  • 👤 Yehuda Lapidot

Bibliographic Details

Application Number —
Jurisdiction US
Data Source google_patents
Last Synchronized 2026-10-28 09:40
CPC Classifications
C; C07; C07H; C07H21/00

Claims Analysis

Total Claims: 9
Claim 1
Independent Claim 41 words
A pharmaceutical composition for inhibiting the immune response of mammals, which comprises as active ingredient an effective dosage of at least one (2'-5')-oligo-isoadenylate of the formula (2'-5')A(pA) n pA wherein n is an integer of 1-6, and a pharmaceutically acceptable excipient.
Claim 2
Dependent Claim 41 words
A pharmaceutical composition for inhibiting the immune response of mammals, which comprises as active ingredient an effective dosage of at least one (2'-5')-oligo-isoadenylate of the formula (2'-5')A(pA) n pA wherein n is an integer of 1-6, and a pharmaceutically acceptable excipient.
Claim 3
Dependent Claim 16 words
A pharmaceutical composition according to claim 1, comprising as active ingredient about 20 to 500 mg/human/day.
Claim 4
Dependent Claim 32 words
A pharmaceutical composition according to claim 1, wherein said active ingredient is a combination of said (2'-5')-oligo-isoadenylates including trimer, tetramer and pentamer and wherein said trimer is present in the preponderant amount.
Claim 5
Independent Claim 40 words
A method for inhibiting the immune response of mammals, comprising administering to a mammal in need of such inhibition an effective amount of at least one compound of the formula (2'-5')A(pA) n pA wherein n is an integer of 1-6.
Claim 6
Independent Claim 40 words
A method for inhibiting the immune response of mammals, comprising administering to a mammal in need of such inhibition an effective amount of at least one compound of the formula (2'-5')A(pA) n pA wherein n is an integer of 1-6.
Claim 7
Dependent Claim 24 words
A method in accordance with claim 4 wherein said compound is administered to a human patient in an amount of 20 to 500 mg/day.
Claim 8
Dependent Claim 18 words
A method in accordance with claim 4 wherein the mammal being treated is one with an autoimmune disease.
Claim 9
Dependent Claim 19 words
A method in accordance with claim 4 wherein the mammal being treated is one about to undergo surgical transplantation.

References Cited (Backward Citations)

US3459637A Cited
US3850749A Cited
US4210746A Cited

USPTO Annuity & Maintenance Windows

Annuity Stage Window Opens Payment Deadline Surcharge Period Until Estimated Fee Status
3.5 Years (Year 4) 1986-03-28 1986-09-27 1987-03-29 $2000.00 Window Closed / Lapsed
7.5 Years (Year 8) 1990-03-28 1990-09-27 1991-03-29 $3760.00 Window Closed / Lapsed
11.5 Years (Year 12) 1994-03-28 1994-09-27 1995-03-29 $7700.00 Window Closed / Lapsed

Assigned Categories & Tags

No categories assigned to this patent yet.

Assign Category Tag